Rani Therapeutics Q3 net loss $18.3M, cash $60.5M, CEO salary cut to $100k, workforce reduced 25%

Rani Therapeutics Holdings, Inc.

2023-Q3 EPS reported $1.06

Net loss $18.3M in Q3 2023 vs $16.2M in Q3 2022; R&D spend $11.2M, cash burn extends runway into 2025.
CEO Talat Imran salary reduced from $520k to $100k through 2024 or until $50M is raised.
Strategic prioritization: discontinue RT-101, pause RT-105/RT-110, workforce cut ~25%.
RT-102 Phase 2 starts year-end 2023; RT-111 Phase 1 topline expected Q1 2024; RaniPill HC Phase 1-ready 2H 2024.
RaniPill HC achieved >90% drug delivery success in preclinical studies with adalimumab and interleukin.

item 2.02 item 5.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Rani Therapeutics Holdings, Inc. reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 8, 2023, Rani Therapeutics Holdings, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the third quarter ended September 30, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Rani Therapeutics Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-061104

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.